Tzana Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 8.52%
(FY 2020)
- Profit -67.64%
(FY 2020)
- Ebitda 16.66%
(FY 2020)
- Net Worth -107.44%
(FY 2020)
- Total Assets -48.23%
(FY 2020)
About Tzana Pharmaceuticals
The Company is engaged in the Electrnoics Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Abdulbijur Vallarkodath, Chundanveetil Najeeb, and Farzana Abdul serve as directors at the Company.
- CIN/LLPIN
U52601KA2017PTC103665
- Company No.
103665
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jun 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Tzana Pharmaceuticals?
Board Members(3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Abdulbijur Vallarkodath | Director | 07-Jun-2017 | Current |
Chundanveetil Najeeb | Director | 07-Jun-2017 | Current |
Farzana Abdul | Additional Director | 12-Jan-2018 | Current |
Financial Performance of Tzana Pharmaceuticals.
Tzana Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 8.52% increase. The company also saw a substantial fall in profitability, with a 67.64% decrease in profit. The company's net worth observed a substantial decline by a decrease of 107.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Tzana Pharmaceuticals?
Unlock access to Tzana Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Avallark Services LlpActive 11 years 8 months
Abdulbijur Vallarkodath and Farzana Abdul are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Tzana Pharmaceuticals?
Unlock and access historical data on people associated with Tzana Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tzana Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tzana Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.